Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 9INDUSTRY 3NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Skin Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Interleukin-2 × Clear all
NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated
25 enrolled 21 charts
Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT00329368 2012-03-09

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Endocyte

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡